Information Provided By: 
Fly News Breaks for August 23, 2016
CELG
Aug 23, 2016 | 11:44 EDT
Cowen analyst Eric Schmidt noted that third-party sources indicate Celgene raised the prices for Revlimid and Pomalyst by 3%, effective earlier this month, marking the third price increase for these drugs over the past 12 months. This pricing activity has been more aggressive than in prior years, noted Schmidt, who has an Outperform rating and $150 price target on Celgene shares.
News For CELG From the Last 2 Days
There are no results for your query CELG
